Lagevrio Shortage: What Providers and Prescribers Need to Know in 2026

As a prescriber, you know that writing a Lagevrio prescription and having your patient actually fill it within the critical 5-day window are two very different challenges. The transition from government-distributed supply to commercial pharmacy channels has introduced persistent access issues for this second-line COVID antiviral. This briefing covers the current state of Lagevrio availability, key prescribing considerations, and practical tools to support your patients.

Supply Chain Status: What's Changed Since 2023

Lagevrio's supply chain has undergone significant changes in the past two years:

Government distribution ended late 2023. After the public health emergency ended, federal procurement and distribution wound down. Only select federal entities (HRSA health centers, VA, Indian Health Service, DoD) retained access to ASPR-procured supply.

All HHS-distributed supply expired February 2025. Federal ordering of Lagevrio for ASPR distribution closed January 22, 2025. All previously distributed HHS stock expired on or before February 27, 2025.

Commercial-only in 2026. All Lagevrio must now be obtained through commercial pharmacy channels. Pharmacies purchase it from distributors and bear the full cost risk.

No official shortage. Lagevrio is not on the FDA or ASHP drug shortage lists. Manufacturing capacity is not the constraint — pharmacy-level stocking practices are.

Clinical Prescribing Considerations for Lagevrio in 2026

Lagevrio (molnupiravir) remains authorized under EUA for adults with mild-to-moderate COVID-19 at high risk for severe disease, when Paxlovid and Remdesivir are not accessible or appropriate. Key clinical considerations:

EUA requirements: Only physicians, APRNs, and PAs licensed to prescribe anti-infectives under state law may prescribe Lagevrio. You must provide patients with the EUA Fact Sheet before they receive the medication.

Pregnancy: Lagevrio carries a boxed warning regarding fetal harm based on animal data. Verify pregnancy status before prescribing. If prescribed to a pregnant patient, extensive counseling and documentation are required.

Contraception counseling: Patients of childbearing potential should use effective contraception during treatment and for 4 days after. Male patients should use contraception for 3 months after the final dose.

Age restriction: Not authorized for patients under 18 due to potential effects on bone and cartilage growth.

Drug interactions: No formal drug interactions have been identified for Lagevrio — making it the preferred option for patients on complex polypharmacy regimens where Paxlovid is contraindicated.

Efficacy: MOVe-OUT trial showed approximately 30% relative risk reduction in hospitalization/death vs. placebo. Less effective than Paxlovid (~89%) but clinically meaningful for appropriate patients.

When to Consider Lagevrio Over Paxlovid

Lagevrio is the preferred choice when:

Paxlovid is contraindicated due to drug interactions (immunosuppressants, certain antiarrhythmics, anticoagulants, HIV medications, or other strong CYP3A4 substrates)

Patient has severe renal impairment (eGFR < 30 mL/min) where Paxlovid is not recommended

Paxlovid is unavailable and no infusion center access exists for Remdesivir

Patient is on complex polypharmacy and medication reconciliation for Paxlovid would cause unsafe treatment delays

Patient Access and Cost: Programs to Know

At a retail price of approximately $1,100–$1,170 for a 5-day course, cost is a significant barrier for uninsured or underinsured patients. Several programs can help:

MerckHelps (merckhelps.com/lagevrio): Merck's patient assistance program provides Lagevrio at no cost to eligible uninsured patients who cannot afford it. Call 1-800-727-5400. Providers can initiate expedited requests by phone.

Merck savings coupon: Privately insured patients may be eligible for a savings coupon at lagevrio.com/patients/coupon, reducing out-of-pocket costs.

Medicare Part D: Lagevrio is typically listed as Tier 1 on Medicare Part D formularies. Copays are generally $10–$50 for most beneficiaries.

Practical Workflow for Providers: Maximizing Prescription Success

When prescribing Lagevrio, consider this workflow to maximize the odds of your patient successfully filling the prescription within the critical window. medfinder for Providers offers tools your care team can use to verify pharmacy availability before sending the prescription:

Confirm availability before sending the prescription — call ahead to pharmacies or use medfinder for Providers to verify stock

Route the prescription to a pharmacy confirmed to have stock

Enroll eligible patients in MerckHelps at the point of prescribing — the program can ship Lagevrio overnight to the patient's address if approved

Have a contingency plan ready — know which local infusion centers offer Remdesivir if Lagevrio cannot be located

For more strategies, see our provider guide on helping patients find Lagevrio in stock.